News | News By Subject | News by Disease News By Date | Search News

Hepatitis-C News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Gilead (GILD) Drops Another Bombshell, Will Shift R&D Cash Away From Hep C     11/7/2016
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it     11/2/2016
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes?     10/18/2016
Achillion (ACHN), Johnson & Johnson (JNJ)'s Hep C Candidate Scores a 100% Cure Rate in Phase IIa Trial     9/9/2016
FDA Green Lights AbbVie (ABBV) Once-Daily Viekira XR for Hepatitis C     7/26/2016
Gilead (GILD)'s Strategy for New Hep C Drug Epclusa     7/7/2016
Regulus (RGLS) Shares Crumble As FDA Puts Hep C Treatment on Hold     6/28/2016
Gilead (GILD)'s Plan to Dominate the Hepatitis C Market     6/27/2016
Two Upstarts that Could Dislodge Gilead (GILD)'s Hold on the Hepatitis C Market     6/22/2016
Federal Judge Reopens Gilead (GILD) Case Amid Allegations Former Merck & Co. (MRK) Scientist Lied     5/3/2016
AbbVie (ABBV)'s New Hep C Regimen Shows High Cure Rates in Mid-Stage Trial     4/18/2016
Merck & Co. (MRK)'s Hep C Drug ZEPATIER Shows Cure Rates as High as 96% in Phase III Studies     4/18/2016
AbbVie (ABBV)'s Hep C Therapy ABT-493 and ABT-530 Show Promise in Pre-Treated Patients     4/15/2016
More Bad Luck for Gilead (GILD) as Merck & Co. (MRK) Wins Victory in Hep C Patent Dispute     3/24/2016
Gilead (GILD), Merck & Co. (MRK) Duke It Out Over Hep C $1,000-Pill Royalties     3/8/2016

News from Around the Web
Gilead (GILD)'s Hep C Med the Most Costly for Medicare, Medicaid in 2015     11/15/2016
University of Pennsylvania Study Looks To Speed Transplants With Hepatitis C-Infected Kidneys     10/28/2016
The Lab Breakthrough And The Two Men Behind Today’s Pricey Hepatitis C Cures     9/13/2016
Vietnam Vets Blame "Jet Guns" For Their Hepatitis C     2/15/2016
One-Step Test For Hepatitis C Virus Infection Developed, University of California, Irvine Health Researchers Reveal     11/16/2015
Gilead (GILD) Beats AbbVie (ABBV) Again     9/22/2015
China Rejects Patent Linked To Gilead (GILD) Hepatitis C Drug     6/22/2015
Gilead (GILD) Holds Cash Overseas to Save Billions on Taxes     2/27/2015
Gilead Sciences, Inc. (GILD)'s $1,000-A-Pill Hepatitis C Drug May Make Financial Sense For Prisons     10/21/2014
Gilead Sciences, Inc. (GILD) Looks To Erase Bristol-Myers Squibb Company (BMY)'s Early Hep C Lead     9/30/2014
What Happened At BioPharm America 2014?     9/24/2014
Hepatitis C Could Become A Rare Disease By 2036, University of Pittsburgh Reveals     8/5/2014
Drugs To Watch: Potential Blockbusters Of 2014     4/17/2014
Enanta Pharmaceuticals, Inc., No Longer Obscure, Eyes Slice Of Big Hepatitis C Market     1/24/2014
Interferon-Free Drugs Show Promise in Fighting Hepatitis C, Goethe University Medical Center Study     8/15/2013

Press Releases
Health Canada Release: Information Update - Direct-Acting Antivirals, Used For Hepatitis C, May Reactivate Hepatitis B     12/2/2016
Achillion (ACHN) Announces Initiation Of Patient Dosing By Janssen Pharmaceutical In A Global, Short Treatment-Duration Phase 2b Study Of JNJ-4178 In Chronic HCV     11/30/2016
Mylan (MYL) Signs Sub-License Agreement With The Medicines Patent Pool To Increase Access To Hepatitis C Treatment In Developing Countries     11/28/2016
AbbVie (ABBV)'s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease     11/15/2016
Enanta Pharmaceuticals, Inc. Announces Abbvie’s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease     11/15/2016
Merck & Co. (MRK) Announces Findings For Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates Of Sustained Virologic Response In People With Genotypes 1, 2 Or 3 Infection     11/14/2016
Eight Weeks Of Treatment With AbbVie (ABBV)'s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes Of Chronic Hepatitis C     11/14/2016
American Association for Study of Liver Diseases Release: Large Study Identifies Increase Of Cirrhosis In Hepatitis C Patients     11/14/2016
American Association for Study of Liver Diseases Release: New Combination Therapy Could Cure Hepatitis C With Only 4 Weeks Of Treatment     11/14/2016
Enanta Pharmaceuticals, Inc. Announces Eight Weeks Of Treatment With AbbVie (ABBV)’s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes Of Chronic Hepatitis C     11/11/2016
TaiGen Biotechnology To Establish A New Company With HEC Pharmaceutical In China For Treatment Of Chronic Hepatitis C     10/31/2016
Gilead (GILD) Announces SVR12 Rates From Four Phase III Studies Of A Once-Daily, Fixed-Dose Combination Of Sofosbuvir, Velpatasvir And Voxilaprevir In Treatment-Naïve And Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients     10/20/2016
FDA Tags AbbVie (ABBV)'s HCV Regimen With Breakthrough Tag     9/30/2016
Achillion (ACHN) Announces 100% SVR12 In The 6-Week And 8-Week Cohorts In Janssen’s Phase II Trial Evaluating The Triple Combination Treatment Regimen Including Odalasvir, AL-335, And Simeprevir For Genotype 1 Treatment-Naïve HCV     9/26/2016
AbbVie (ABBV) Presents Data On Eight-Week Treatment Of VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C     9/23/2016

//-->